Chronos Archive seal
The Human Record

Ella Fitzgerald

Case HR-ML029-TD · Modern EHR teaching episode · Draft for review

Review summary

Historical dates
April 25, 1917 – June 15, 1996
Synthetic DOB
1917-04-25
Index visit
1987-05-11 at age 70
Synthetic MRN
HR-ML029-SYN-TD

Teaching objective: Limb-, sight- and heart-protecting primary care for a 70-year-old touring singer with type 2 diabetes, peripheral artery disease with claudication, diabetic macular edema, and coronary bypass surgery the year before: the comprehensive diabetic foot examination (inspection, 10-g monofilament, vibration, pulses) with the ankle- and toe-brachial indices, IWGDF risk grading and a high-risk foot program with podiatry and stage footwear; prompt vascular surgery evaluation, supervised exercise therapy, and a clear plan for revascularization if symptoms limit her life; a high-intensity statin with ezetimibe to an LDL below 55 mg/dL, aspirin with low-dose rivaroxaban, and glucose-lowering medicines with cardiovascular and kidney benefit (empagliflozin, then semaglutide) in place of a sulfonylurea; retinal care with anti-VEGF injections; kidney monitoring; hypoglycemia safety on tour (insulin timing across time zones, a continuous glucose monitor, glucagon, and a show-day plan); and the equity and access steps that make this care reach her, on the ADA Standards of Care 1987, the IWGDF 1984 guidelines, the 1985 ACC/AHA lower extremity PAD guideline, and the CMID diabetes monograph.

Historical timeline

DateEventClaims
April 25, 1917Born in Newport News, Virginia.CLM-0001
1932Mother died; placed in an orphan asylum at 15.CLM-0002
1934Won the Apollo Theater amateur contest.CLM-0003
1958First Grammy Award.CLM-0004
1970sHealth problems began; diabetes affected her eyes; cataract surgery, then touring more than 40 weeks a year.CLM-0007, CLM-0008
1986Intensive care for heart trouble; quintuple-bypass heart surgery.CLM-0009
1989Spoke of missing the road during her convalescence.CLM-0013
1992National Medal of Freedom.CLM-0005
1993Both legs amputated below the knee; created her charitable foundation.CLM-0010, CLM-0011, CLM-0012
June 15, 1996Died at home in Beverly Hills.CLM-0014

Evidence claims

D = documented, R = retrospective, S = synthetic.

GradeClaimCertaintySources
D Ella Jane Fitzgerald was born on April 25, 1917, in Newport News, Virginia, to Temperance and William Fitzgerald. Most biographies gave 1918, but her birth certificate and school records show 1917. confirmed Ella Fitzgerald: career timeline supports
'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports
HISTMED Master Roster v3 context
D In 1932 her mother died suddenly of a heart attack; orphaned at 15, she was placed in the Colored Orphan Asylum in Riverdale, New York.
Family history from the cited source; age at death not given.
confirmed Ella Fitzgerald: career timeline supports
D In 1934 she won an amateur contest at the Apollo Theater in Harlem, which brought her to the attention of the drummer and bandleader Chick Webb; she made her first recording with his band in 1935, and her 1938 swing version of the nursery rhyme "A-Tisket, A-Tasket" became her first hit.
Her life as a performing singer anchors the modern social history.
confirmed 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports
Ella Fitzgerald: career timeline supports
D She won the Grammy Award for Best Jazz Individual Performance in 1958 for Ella Fitzgerald Sings the Duke Ellington Song Book, and received the Kennedy Center award for lifetime achievement in 1979. She was known as America's first lady of song.
Achievement and identity, recorded as strengths.
confirmed Ella Fitzgerald: career timeline supports
Ella Fitzgerald, 1917-1996: America's First Lady of Song supports
D She was awarded the National Medal of Freedom in 1992.
After the index date.
confirmed Ella Fitzgerald: career timeline supports
D She began to have health problems during the 1970s; she had diabetes, which caused problems with her eyes.
The anchor for the modern diabetic retinopathy. The type of diabetes and its treatment were not made public.
confirmed Ella Fitzgerald, 1917-1996: America's First Lady of Song supports
D In the 1970s, after cataract surgery, she returned to touring more than 40 weeks a year.
The anchor for the lens implants in the modern eye examination and for her touring life.
confirmed Scat lady supports
D In 1986 she was admitted to intensive care for heart trouble and underwent quintuple-bypass heart surgery; the following year she was back onstage.
The anchor for the modern coronary artery disease after bypass surgery the year before the index visit.
confirmed Ella Fitzgerald: career timeline supports
Scat lady supports
Ella Fitzgerald, 1917-1996: America's First Lady of Song supports
D She had been suffering from diabetes and its circulatory system complications for many years before her death.
The anchor for the modern peripheral artery disease. Reported at her death; no fetched source dates the start of the circulatory complications.
confirmed 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports
D In 1993 both of her legs were amputated below the knees because of complications of diabetes.
After the index date; history only. The modern episode does not stage or predict this outcome.
confirmed 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports
Scat lady supports
Ella Fitzgerald, 1917-1996: America's First Lady of Song supports
D In 1993 she created and funded the Ella Fitzgerald Charitable Foundation, whose areas of interest include medical care and research with an emphasis on diabetes, vision problems, and heart disease.
After the index date; recorded as a strength and as the conditions she chose to name.
confirmed The Ella Fitzgerald Charitable Foundation supports
D In 1989, asked how she spent her convalescence, she said: "Staying home and being bored. I miss the road. I miss going overseas."
Her own public words, after the index date; they show what performing and travel meant to her.
confirmed Scat lady supports
D She died at home in Beverly Hills, California, on June 15, 1996, at 79. The exact cause of death was not released; one public timeline attributes it to complications of diabetes.
History only; recorded in one sentence.
confirmed 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style supports
Scat lady supports
Ella Fitzgerald: career timeline supports

Modern synthetic problem list

GradeProblemClinical statusVerificationPlacementHistorical claims
S Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications active confirmed active CLM-0007, CLM-0010
S Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems active confirmed active CLM-0007, CLM-0008
S Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery active confirmed active CLM-0009

Synthetic outcome measures

GradeDateMeasureResultCoding
S 1987-05-11 Hemoglobin A1c/Hemoglobin.total in Blood 8.6% (high)
Reference Below 5.7% is normal; her individualized goal is below 7.5%
http://loinc.org · 4548-4
S 1987-05-11 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1987-05-11 Potassium [Moles/volume] in Serum or Plasma 4.4 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1987-05-11 Creatinine [Mass/volume] in Serum or Plasma 0.92 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1987-05-11 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M 67 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1987-05-11 Glucose [Mass/volume] in Serum or Plasma 168 mg/dL (high)
Reference 70-99 mg/dL
http://loinc.org · 2345-7
S 1987-05-11 Albumin/Creatinine [Mass Ratio] in Urine 18 mg/g
Reference <=30 mg/g
http://loinc.org · 9318-7
S 1987-05-11 Cholesterol [Mass/volume] in Serum or Plasma 164 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1987-05-11 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 92 mg/dL
Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL
http://loinc.org · 13457-7
S 1987-05-11 Cholesterol in HDL [Mass/volume] in Serum or Plasma 44 mg/dL (low)
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 1987-05-11 Triglyceride [Mass/volume] in Serum or Plasma 140 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1987-05-11 Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 U/L
Reference 7-35 U/L
http://loinc.org · 1742-6
S 1987-05-11 Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 U/L
Reference 10-35 U/L
http://loinc.org · 1920-8
S 1987-05-11 Hemoglobin [Mass/volume] in Blood 12.4 g/dL
Reference 11.6-15 g/dL
http://loinc.org · 718-7
S 1987-05-11 Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 386 pg/mL
Reference 232-1245 pg/mL
http://loinc.org · 2132-9
S 1987-05-11 Ankle-brachial index 0.62 (low)
Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal
http://loinc.org · 77194-9
S 1987-05-11 Ankle-brachial index 0.74 (low)
Reference 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal
http://loinc.org · 77194-9
S 1987-05-11 Toe brachial index - right 0.46 (low)
Reference Above 0.70 normal
http://loinc.org · 77618-7
S 1987-05-11 Toe brachial index - left 0.55 (low)
Reference Above 0.70 normal
http://loinc.org · 77617-9
S 1987-05-11 Visual acuity best corrected Right eye by ETDRS eye chart 64 (low)
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79876-9
S 1987-05-11 Visual acuity best corrected Left eye by ETDRS eye chart 81
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79877-7
S 1987-06-15 Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 http://loinc.org · 55758-7
S 1987-06-15 Total score [Mini-Cog] 5 http://loinc.org · 72233-0
S 1987-06-15 Total score [AUDIT-C] 1 http://loinc.org · 75626-2
S 1987-08-10 Hemoglobin A1c/Hemoglobin.total in Blood 7.6% (high)
Reference Below 5.7% is normal; her individualized goal is below 7.5%
http://loinc.org · 4548-4
S 1987-08-10 Sodium [Moles/volume] in Serum or Plasma 140 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1987-08-10 Potassium [Moles/volume] in Serum or Plasma 4.6 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1987-08-10 Creatinine [Mass/volume] in Serum or Plasma 0.96 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1987-08-10 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M 64 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1987-08-10 Cholesterol [Mass/volume] in Serum or Plasma 128 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1987-08-10 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 64 mg/dL
Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL
http://loinc.org · 13457-7
S 1987-08-10 Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 mg/dL (low)
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 1987-08-10 Triglyceride [Mass/volume] in Serum or Plasma 112 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1987-08-10 Visual acuity best corrected Right eye by ETDRS eye chart 71 (low)
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79876-9
S 1987-08-10 Visual acuity best corrected Left eye by ETDRS eye chart 81
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79877-7
S 1987-10-26 Hemoglobin A1c/Hemoglobin.total in Blood 7.1% (high)
Reference Below 5.7% is normal; her individualized goal is below 7.5%
http://loinc.org · 4548-4
S 1987-10-26 Sodium [Moles/volume] in Serum or Plasma 139 mmol/L
Reference 135-145 mmol/L
http://loinc.org · 2951-2
S 1987-10-26 Potassium [Moles/volume] in Serum or Plasma 4.5 mmol/L
Reference 3.5-5.1 mmol/L
http://loinc.org · 2823-3
S 1987-10-26 Creatinine [Mass/volume] in Serum or Plasma 0.94 mg/dL
Reference 0.59-1.04 mg/dL
http://loinc.org · 2160-0
S 1987-10-26 Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M 65 mL/min/1.73 m²
Reference >=60 mL/min/1.73 m²
http://loinc.org · 98979-8
S 1987-10-26 Cholesterol [Mass/volume] in Serum or Plasma 114 mg/dL
Reference <=199 mg/dL
http://loinc.org · 2093-3
S 1987-10-26 Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 48 mg/dL
Reference Her goal with coronary and peripheral artery disease is below 55 mg/dL
http://loinc.org · 13457-7
S 1987-10-26 Cholesterol in HDL [Mass/volume] in Serum or Plasma 47 mg/dL (low)
Reference >=50 mg/dL
http://loinc.org · 2085-9
S 1987-10-26 Triglyceride [Mass/volume] in Serum or Plasma 96 mg/dL
Reference <=149 mg/dL
http://loinc.org · 2571-8
S 1987-10-26 Visual acuity best corrected Right eye by ETDRS eye chart 75 (low)
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79876-9
S 1987-10-26 Visual acuity best corrected Left eye by ETDRS eye chart 81
Reference 85 letters is about 20/20; 80 about 20/25; 65 about 20/50
http://loinc.org · 79877-7

Synthetic vital signs

DateMeasureResultLOINCGrade
1987-05-11Body height165 cm8302-2S
1987-05-11Body weight84 kg29463-7S
1987-05-11Body mass index (BMI) [Ratio]30.9 kg/m239156-5S
1987-05-11Systolic blood pressure126 mm[Hg]8480-6S
1987-05-11Diastolic blood pressure70 mm[Hg]8462-4S
1987-05-11Heart rate62 /min8867-4S
1987-05-11Respiratory rate16 /min9279-1S
1987-05-11Body temperature36.6 Cel8310-5S
1987-05-11Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1987-05-26Body height165 cm8302-2S
1987-05-26Body weight83.8 kg29463-7S
1987-05-26Body mass index (BMI) [Ratio]30.8 kg/m239156-5S
1987-05-26Systolic blood pressure124 mm[Hg]8480-6S
1987-05-26Diastolic blood pressure70 mm[Hg]8462-4S
1987-05-26Heart rate60 /min8867-4S
1987-05-26Respiratory rate16 /min9279-1S
1987-05-26Body temperature36.5 Cel8310-5S
1987-05-26Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1987-08-10Body height165 cm8302-2S
1987-08-10Body weight82.1 kg29463-7S
1987-08-10Body mass index (BMI) [Ratio]30.2 kg/m239156-5S
1987-08-10Systolic blood pressure122 mm[Hg]8480-6S
1987-08-10Diastolic blood pressure68 mm[Hg]8462-4S
1987-08-10Heart rate62 /min8867-4S
1987-08-10Respiratory rate16 /min9279-1S
1987-08-10Body temperature36.6 Cel8310-5S
1987-08-10Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S
1987-10-26Body height165 cm8302-2S
1987-10-26Body weight80.6 kg29463-7S
1987-10-26Body mass index (BMI) [Ratio]29.6 kg/m239156-5S
1987-10-26Systolic blood pressure120 mm[Hg]8480-6S
1987-10-26Diastolic blood pressure68 mm[Hg]8462-4S
1987-10-26Heart rate60 /min8867-4S
1987-10-26Respiratory rate16 /min9279-1S
1987-10-26Body temperature36.6 Cel8310-5S
1987-10-26Oxygen saturation in Arterial blood by Pulse oximetry98 %59408-5S
1987-06-15Body height165 cm8302-2S
1987-06-15Body weight83.4 kg29463-7S
1987-06-15Body mass index (BMI) [Ratio]30.6 kg/m239156-5S
1987-06-15Systolic blood pressure124 mm[Hg]8480-6S
1987-06-15Diastolic blood pressure68 mm[Hg]8462-4S
1987-06-15Heart rate60 /min8867-4S
1987-06-15Respiratory rate16 /min9279-1S
1987-06-15Body temperature36.6 Cel8310-5S
1987-06-15Oxygen saturation in Arterial blood by Pulse oximetry97 %59408-5S

Social, functional, and mental status

Social history

Functional status

Mental status

Allergies and medications

Allergies

Medications

Procedures and immunizations

Procedures

Immunizations

Past medical history

True biography with historical dates; not part of the synthetic care timeline.

Family history

Care-plan goals

GoalTarget dateStatusOutcome
No glucose below 70 mg/dL on most days and no level 2 or 3 low (below 54 mg/dL or needing help) through six months1987-10-26completedNo level 2 or 3 lows since intake; time below 70 mg/dL under 1%
A1c below 7.5% by six months1987-10-26completedA1c 7.1%
LDL cholesterol below 55 mg/dL by six months1987-10-26completedLDL 48 mg/dL on atorvastatin 80 mg and ezetimibe
Walk at least four blocks without stopping by six months1987-10-26completedWalks about five blocks before calf pain
No foot ulcer, and protective footwear on and off stage, through six months1987-10-26completedNo ulcer; low-heeled custom stage shoes and protective daily shoes

Interventions

InterventionStatusGuideline
Comprehensive diabetic foot program: foot inspection, monofilament and vibration testing, and pulses at every visit; IWGDF risk category 2 with podiatry every three months for callus and nail care; protective daily shoes and low-heeled custom stage shoes; daily self-inspection with a magnifying mirror or her dresser's help; and same-day care for any blister, wound, or color changecompletedGL-IWGDF-2023, GL-ADA-2026, GL-CMID-2026
Vascular surgery consultation for claudication with an ankle-brachial index of 0.62: arterial duplex, supervised exercise therapy, and whether and when revascularization should be considered, before any loss of tissuecompletedGL-ACC-PAD-2024, GL-IWGDF-PAD-2023
Hypoglycemia safety on tour: glipizide stopped; glargine reduced 20% and moved to the morning, at a fixed clock time with written time-zone steps; a continuous glucose monitor with low alerts shared, with her consent, with her road manager; a glucose check before each show and a meal before late shows; glucose tablets in the dressing room and at the side of the stage; nasal glucagon with the road manager trained; and the beta-blocker's effect on warning signs explainedcompletedGL-ADA-2026, GL-CMID-2026
Glucose-lowering medicines with heart and kidney benefit: empagliflozin 10 mg started, with sick-day rules (hold on days she cannot eat or drink and before surgery), genital hygiene advice, and a foot check at each visit; metformin continued with vitamin B12 checked; A1c every three months until at goal (goal below 7.5%)completedGL-ADA-2026, GL-CMID-2026
Cardiovascular protection: atorvastatin raised to 80 mg with a lipid panel 4 to 12 weeks later and a goal LDL below 55 mg/dL; aspirin and metoprolol continued; blood pressure goal below 130/80 mmHgcompletedGL-ADA-2026, GL-ACC-PAD-2024, GL-AHA-CCD-2023, GL-CMID-2026
Eye care: retina clinic appointment within two weeks for the right macular edema, for anti-VEGF injections; retinal examination of both eyes at least yearly and more often while being treated; large-print materialscompletedGL-ADA-2026, GL-CMID-2026
Kidney and laboratory monitoring: creatinine, eGFR and potassium at three months and then every six to twelve months, urine albumin-creatinine ratio yearly, liver tests after the statin change if symptoms, and vitamin B12 periodically on metformincompletedGL-ADA-2026, GL-CMID-2026
Access and equity: scheduling around tour dates, video visits on the road, large-print instructions, drug-cost checks before prescribing, coordination with clinics in tour cities, and diabetes self-management education and medical nutrition therapy timed to her touringcompletedGL-ADA-2026, GL-ACC-PAD-2024
Supervised exercise therapy for claudication: treadmill walking to moderate calf pain, 30 to 45 minutes three times a week for twelve weeks at a hospital program, with a structured home walking plan for tour weeks; then walking at least three times a week for lifecompletedGL-ACC-PAD-2024
Low-dose rivaroxaban 2.5 mg twice daily with aspirin 81 mg to lower the risk of heart attack, stroke, and major limb events, with bleeding precautions and no anti-inflammatory painkillerscompletedGL-ACC-PAD-2024, GL-ADA-2026
Revascularization plan: no procedure now; endovascular treatment of the right superficial femoral artery to be considered if claudication still limits her life after twelve weeks of supervised exercise and medical therapy; urgent vascular review for rest pain, a wound, or color change; ankle-brachial index and duplex at six monthscompletedGL-ACC-PAD-2024, GL-IWGDF-PAD-2023
Semaglutide 0.25 mg weekly for four weeks, then 0.5 mg weekly, for cardiovascular benefit and walking distance, with the retina clinic told before the start because a fast fall in glucose can briefly worsen retinopathy; ezetimibe 10 mg added for an LDL of 64 mg/dLcompletedGL-ADA-2026, GL-STRIDE-2025, GL-CMID-2026

Planned encounters

Supporting documents

C-CDA note documents

Each link opens a readable copy; the XML beside it is the exchange file.

Sources

IDSourcePublisherType
SRC-0001 'The Greatest': Ella Fitzgerald dies; singer expanded boundaries of jazz with warm sound, acrobatic style The Spokesman-Review (wire reports) other
SRC-0002 Ella Fitzgerald: career timeline American Masters, PBS (WNET) biography
SRC-0003 Scat lady Newsweek other
SRC-0004 Ella Fitzgerald, 1917-1996: America's First Lady of Song VOA Learning English (Voice of America) government
SRC-0005 The Ella Fitzgerald Charitable Foundation The Ella Fitzgerald Charitable Foundation (official site) primary
SRC-0008 HISTMED Master Roster v3 The Human Record project other

Review status

ReviewStatusNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the hypoglycemia plan (glipizide stopped, glargine reduced and moved to the morning), empagliflozin and semaglutide with peripheral artery disease and retinopathy, low-dose rivaroxaban with aspirin, the decision to defer revascularization during supervised exercise therapy, and the IWGDF risk grading.
provenance reviewnot_startedA 1996 wire obituary, the PBS American Masters timeline, a Newsweek obituary, VOA Learning English, and the official foundation page are logged. Every health claim is from these public reports; the type of diabetes and all modern findings are synthetic.
safe messaging reviewnot_startedRecent-death rule applies. The 1993 amputations and her death are recorded as history only, in plain sentences; the modern episode does not stage or predict them. No mental-health or substance claim is made.

Comments and corrections

Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.

Comments appear on the online version of this page.